While inhibiting LCAT may lead to the problems associated with FLD, due to age of onset with the symptoms of FLD not manifesting until middle age, LCAT inhibition may be a reasonable course of treatment management for LAL deficiency patients (Wolska and Remaley, 2021; Feingold, 2022). This evidence concerns the gene LIPA and Familial LCAT deficiency.